SHORT COMMUNICATIONSCDKN2A germline alterations in melanoma patients with personal or familial history of pancreatic cancerDe Unamuno, Blancaa; García-Casado, Zaidab; Bañuls, Josée; Requena, Celiac; Lopez-Guerrero, José Antoniob; Nagore, Eduardoc,dAuthor Information aDepartment of Dermatology, Hospital Universitario y Politécnico de La Fe bDepartment of Dermatology, Laboratory of Molecular Biology cDepartment of Dermatology, Instituto Valenciano de Oncología dSchool of Medicine, Universidad Católica de Valencia San Vicente Martir, València eDepartment of Dermatology, Hospital General Universitario de Alicante, Alacant, Spain Correspondence to Eduardo Nagore, MD, Department of Dermatology, Instituto Valenciano de Oncología, c/Profesor Beltrán Báguena, 8, 46009 València, Spain Tel/fax: +34 961 114 015; e-mail: [email protected] Melanoma Research: June 2018 - Volume 28 - Issue 3 - p 246-249 doi: 10.1097/CMR.0000000000000442 Buy SDC Metrics Abstract CDKN2A germline mutations increase the risk of melanoma development and are present in 20 and 10% of familial and multiple melanoma cases, respectively. Pancreatic cancer has been associated with CDKN2A in some populations and, accordingly, its presence in first-degree or second-degree relatives of a melanoma patient is considered as a criterion for genetic testing. In this study, we show that in an area with low melanoma incidence, CDKN2A germline mutations in patients with melanoma and personal or family history of pancreatic cancer are mainly present in the setting of familial or multiple melanoma cases. In addition, a relatively young age (≤52 years) at pancreatic diagnosis is an additional single criterion that might also be considered. Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.